Your browser doesn't support javascript.
loading
Development of virus-like particles with inbuilt immunostimulatory properties as vaccine candidates.
Collett, Simon; Earnest, Linda; Carrera Montoya, Julio; Edeling, Melissa A; Yap, Ashley; Wong, Chinn Yi; Christiansen, Dale; Roberts, Jason; Mumford, Jamie; Lecouturier, Valerie; Pavot, Vincent; Marco, Sergio; Loi, Joon Keit; Simmons, Cameron; Gulab, Shivali A; Mackenzie, Jason M; Elbourne, Aaron; Ramsland, Paul A; Cameron, Garth; Hans, Dhiraj; Godfrey, Dale I; Torresi, Joseph.
Afiliación
  • Collett S; School of Science, College of Science, Engineering and Health, RMIT University, Melbourne, VIC, Australia.
  • Earnest L; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, VIC, Australia.
  • Carrera Montoya J; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, VIC, Australia.
  • Edeling MA; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, VIC, Australia.
  • Yap A; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, VIC, Australia.
  • Wong CY; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, VIC, Australia.
  • Christiansen D; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, VIC, Australia.
  • Roberts J; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Mumford J; Department of Infectious Diseases, The University of Melbourne at the Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Lecouturier V; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Pavot V; Sanofi-Pasteur, Lyon, France.
  • Marco S; Sanofi-Pasteur, Lyon, France.
  • Loi JK; Sanofi-Pasteur, Lyon, France.
  • Simmons C; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, VIC, Australia.
  • Gulab SA; Institute of Vector-Borne Disease, Monash University, Clayton, VIC, Australia.
  • Mackenzie JM; Avalia Immunotherapies Limited, Wellington, New Zealand.
  • Elbourne A; Vaccine Alliance Aotearoa New Zealand, Wellington, New Zealand.
  • Ramsland PA; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, VIC, Australia.
  • Cameron G; School of Science, College of Science, Engineering and Health, RMIT University, Melbourne, VIC, Australia.
  • Hans D; School of Science, College of Science, Engineering and Health, RMIT University, Melbourne, VIC, Australia.
  • Godfrey DI; Department of Surgery Austin Health, University of Melbourne, Heidelberg, VIC, Australia.
  • Torresi J; Department of Immunology, Central Clinical School, Monash University, Melbourne, VIC, Australia.
Front Microbiol ; 14: 1065609, 2023.
Article en En | MEDLINE | ID: mdl-37350788
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Front Microbiol Año: 2023 Tipo del documento: Article País de afiliación: Australia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Front Microbiol Año: 2023 Tipo del documento: Article País de afiliación: Australia